Skip to main content

Table 2 Patient disposition, Re-treatment and reasons for discontinuation

From: Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study

Parameter Group 1 (1 × 6 mL) Group 2 (1 × 4 mL) Group 3 (2 × 4 mL) Group 4 (3 × 4 mL) Group 5 (3 × 2 mL) Overall N (%)
Number of patients enrolled 20 21 19 20 20 100
Randomised 20 21 20 20 21 100 (100)
Completed study 20 20 19 20 19 98 (98)
Discontinued study 0 1 1 0 2 4 (4)
 Adverse event 0 0 0 0 1 1 (1)
 Wished to withdraw 0 0 1 0 0 1 (1)
 Lack of efficacy 0 1 0 0 0 1 (1)
 Other 0 0 0 0 1 1 (1)
Re-treated
 Number of patients enrolled 3 4 7 5 5 24
 Completed study 3 4 7 4 5 23 (95.8)
 Discontinued study 0 0 0 1 0 1 (4.2)
  Adverse event 0 0 0 1 0 1 (4.2)
Not re-treated
 Number of patients enrolled 12 9 10 12 11 54
Completed study 12 9 9 12 10 52 (96.3)
Discontinued study 0 0 1 0 1 2 (3.7)
 Lost to follow-up 0 0 1 0 1 2 (3.7)